Publications by authors named "B Alcazar-Navarrete"
Objective: This study aimed to evaluate clinical control in chronic obstructive pulmonary disease (COPD), the consequences in terms of treatment decisions, and their potentially associated factors during follow-up of patients in real-life clinical practice.
Methods: EPOCONSUL 2021 is a cross-sectional audit that evaluated the outpatient care provided to patients with a diagnosis of COPD in respiratory clinics in Spain and multivariable logistic regression models to assess the relationships between clinical control and clinical inertia.
Results: 4225 patients from 45 hospitals in Spain were audited.
Resectable Non-Small Cell Lung Cancer Heterogeneity and Recurrence Assessed by Tissue Next-Generation Sequencing Genotyping and Circulating Tumor Cell EZH2 Characterization.
Arch Bronconeumol
October 2024
Introduction: Non-small cell lung cancer (NSCLC) is the most common type of lung neoplasm. Despite surgical resection, it has a high relapse rate, accounting for 30-55% of all cases. Next-generation sequencing (NGS) based on a customized gene panel and the analysis of circulating tumor cells (CTCs) can help identify heterogeneity, stratify high-risk patients, and guide treatment decisions.
View Article and Find Full Text PDFIntrathecal drug delivery (IDD) is part of the fourth analgesic step. Evidence on the quality of life of patients with refractory chronic non-cancer pain (CNCP) using these devices and their long-term outcomes is scarce. This study aims to evaluate patients with IDD to assess their HRQoL.
View Article and Find Full Text PDFArticle Synopsis
- The ANTES B+ study evaluates whether adding an inhaled corticosteroid (ICS) to a combination of long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) improves clinical control in GOLD B COPD patients who are still symptomatic despite current treatment.
- It will involve 1028 patients who will either continue their current LABA/LAMA regimen or switch to a new triple therapy for a year, measuring outcomes like clinical control, exacerbation rates, and lung function.
- The study is significant as it is the first to test this approach in a specific COPD patient group and to use a composite index to measure primary outcomes, with results expected by early 2026.
Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study.
BMJ Open Respir Res
April 2024
Background: Idiopathic pulmonary fibrosis (IPF) is a rare disorder associated with increased mortality and morbidity. There are currently two drugs approved for IPF but their safety and efficacy profile in real-world settings in Spain is not well understood.
Methods: An observational, multicentre, prospective study was carried out among patients with IPF who started treatment with pirfenidone or nintedanib from 2015 to 2021.